Newsroom

Page Meta: of 97 press releases

Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease

Freeline to Present at 22nd Annual Needham Virtual Healthcare Conference

Freeline Reports Full Year 2022 Financial Results and Provides Corporate Update

Freeline Therapeutics to Host Full Year 2022 Financial Results Call

Freeline Announces Closing of Sale of Its CMC-Focused German Subsidiary

Freeline Reports January 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Freeline Publishes Preclinical Proof-of-Concept Data for FLT190, its AAV Gene Therapy Candidate for Fabry Disease, in the Nature Journal Gene Therapy

Freeline Reports December 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Freeline Receives Approval to Transfer to Nasdaq Capital Market

Freeline Reports Third Quarter 2022 Financial Results and Corporate Update

Freeline to Present at the Stifel Healthcare Conference

For all media enquiries please get in touch

media@freeline.life